secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001193125-24-273688
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell reports 94% ORR, 71% CR for IMPT-314 in Phase 1-2 large B-cell lymphoma trial
--------------------------------------------------------------------------------

- Objective response rate 94% (16/17) and complete response rate 71% (12/17) in CAR T-naive patients with ≥2 prior therapies.
- No Grade 3+ cytokine release syndrome; Grade 3 ICANS in 13% (3/23) with median resolution time of 5 days.
- Median follow-up 6.3 months; 71% of patients remained in response at last follow-up.
- Plans to initiate a pivotal trial in 2025 for 3rd-line+ large B-cell lymphoma and continues 2nd-line evaluation.
- Final product enriched for naïve/central memory T cells (median 91%), linked to improved overall survival in other studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524273688/0001193125-24-273688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524273688/d873794d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-273688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer